title: Cilostazol attenuates spontaneous microaggregation of platelets in type 2 diabetic patients with insufficient platelet response to aspirin.
authors.forename: Shin-ichi
authors.initials: S
authors.lastname: Araki
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Matsuno
authors.forename: Masakazu
authors.initials: M
authors.lastname: Haneda
authors.forename: Daisuke
authors.initials: D
authors.lastname: Koya
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Kanno
authors.forename: Shiniji
authors.initials: S
authors.lastname: Kume
authors.forename: Keiji
authors.initials: K
authors.lastname: Isshiki
authors.forename: Hisazumi
authors.initials: H
authors.lastname: Araki
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ugi
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Kawai
authors.forename: Atsunori
authors.initials: A
authors.lastname: Kashiwagi
authors.forename: Takashi
authors.initials: T
authors.lastname: Uzu
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Maegawa
mesh_terms: D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D000077407:Cilostazol; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013777:Tetrazoles / Q000627:therapeutic use*
chemical_list: D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D000077407:Cilostazol; D001241:Aspirin